Transense Technologies PLC
13 December 2007
Transense Technologies plc
('Transense' or the 'Company')
Grant of options
The Company announces that on 12 December 2007 the remaining 50,000 options over
ordinary shares of 10 pence each under the Transense 2005 Unapproved
Discretionary Share Option Scheme were granted to Dr. Raymond Lohr, technical
director of the Company.
Director Options Granted Total Number of Shares under Option*
Raymond Lohr 50,000 @ 28 pence 250,000
* Remaining 200,000 shares under the Transense 2005 Unapproved Discretionary Share Option Scheme have an exercise price
of 100 pence.
All of the options issued on 12 December 2007 are exercisable between 12 December 2010 and 11 December 2012.
In addition, Dr Lohr has an interest in 20,000 ordinary shares in the Company and 90,000 options over ordinary shares of
10 pence each under the Transense 2005 Enterprise Management Incentive Share Option Scheme which have an exercise price
of 100 pence.
Enquiries:
Transense Technologies plc (Jim Perry / Howard Pearl) 01869 238 380
Noble & Company Limited (John Llewellyn-Lloyd / Graeme Bayley) 020 7763 2200
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.